| 241 | 1 | 57 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨替罗非班引起血小板减少的危险因素。方法收集2013年1月至2014年6月734例接受替罗非班抗栓治疗的冠状动脉粥样硬化患者的临床资料,根据用药后血小板计数分为血小板减少组和血小板未减少组,收集相关临床危险因素,并进行Logistic逐步分析,计算各危险因素的比值比及其95%置信区间。结果入组患者中69例患者发生了血小板减少。Logistic多因素逐步回归分析显示,年龄>65岁(OR=2.58,95%CI:1.54-4.33,P<0.05),用药前丙氨酸转氨酶>75 U·L-1(OR=2.39,95%CI:1.26-4.58,P<0.05)和用药前肾小球滤过率<60 mL·min-1·1.73 m-2(OR=3.34,95%CI:1.89-5.88,P<0.05)为独立危险因素。出现血小板减少的中位时间和停药后血小板恢复的中位时间均为1 d。结论高龄、丙氨酸转氨酶升高和肾功能不全为替罗非班相关血小板减少的主要危险因素,因此对于此类患者需密切监测血小板计数,降低出血风险。
Abstract：AIM To investigate the risk factors of thrombocytopenia associated with tirofiban.METHODS The clinical data of 734 patients receiving tirofiban with coronary atherosclerosis disease in our hospital from January 2013 to June 2014 were collected and retrospectively analyzed.The patients were divided into the thrombocytopenia group and normal platelet group according to the platelet count.Logistic regression analysis was performed to screen the related risk factors from the clinical data,and to calculate the odds ratio and 9.5%confidence interval.RESULTS Totally 734 patients were comprised of 588 male(80.1%) and 146 female(19.9%) with mean age of(62.2±11.2) years and mean weight of(69.6 ± 7.9) kg.Among them,thrombocytopenia occurred in 69 patients,multiple factors stepwise logistic regression analysis revealed the following results:the incidence of thrombocytopenia with a higher prevalence in the elder(age>65 years)(OR=2.58,95%CI:1.54-4.33,P<0.05),serum alanine aminotransferase >75U·L-1(OR=2.39,95%CI:1.26-4.58,P<0.05).estimated glomerular filtration rate < 60 mL·min-1?1.73 m-2(OR=3.34,95%CI:1.89- 5.88,P<0.05) before medication.The median time of the occurrence and recovery after drug discontinuance of thrombocytopenia was 1 day.CONCLUSION The elder,elevated alanine aminotransferase and renal dysfunction before medication may be the major risk factors of tirofiban associated thrombocytopenia.Closely monitoring the platelet count for the patients who are prescribed with tirofiban are highly recommended so as to reduce the risk of bleeding.
[1]Kushner FG,Ascheim DD,Albert NM,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the american college of cardiology foundation/american heart association task force on practice guidelines[J].J Am Coll Cardiol 2013,61(4):e78.
[2]Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction-2002:summary article:a report of the American College of Cardiology/American Heart Association task force on practice guidelines(committee on the management of patients with unstable angina)[J].Circulation,2002,106(14):1893.
[3]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2014,35(37):2541.
[4]替罗非班治疗冠状动脉粥样硬化性心脏病专家共识组.替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J].中华内科杂志,2013,52(5):434.
[5]Kereiakes DJ,Berkowitz SD,Lincoff AM,et al.Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoproteinⅡb/Ⅲa blockade[J].Am Heart J,2000,140(1):74.
[6]McKenzie SE,Sachais BS.Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia[J].Curr Opin Hematol,2014,21(5):380.
[7]CTCAE v4.0.Common Terminology Criteria for Adverse Events[EB/OL].[2011/09/01]http://www.calgb.org/Public/meetings/presentations/2009/summer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
[8]Bougie DV,Wilker PR,Wuitschick ED,et al.Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPⅡb/Ⅲa[J].Blood,2002,100(6):2071.
[9]The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS)Study Investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[J].N Engl J Med,1998,338(21):1488.
[10]The RESTORE Investigators.Effects of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.The RESTORE investigators:randomized efficacy study of tirofiban for outcomes and restenosis[J].Circulation,1997,96(5):1445.
[11]The PRISM study Investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina:platelet receptor inhibition in ischemic syndrome management(PRISM)study investigators[J].N Engl J Med,1998,338(21):1498.
[12]Said SM,Hahn J,Schleyer E,et al.GlycoproteinⅡb/Ⅲa inhibitor induced thrombocytopenia diagnosis and treatment[J].Clin Res Cardiol,2007,96(2):61.
[13]Januzzi JL Jr,Snapinn SM,DiBattiste PM,et al.Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency:results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms(PRISM-PLUS)trial[J].Circulation,2002,105(20):2361.
[14]Ikuta S,Tanimura K,Yasui C,et al.Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery[J].J infection chemother,2011,17(3):388.
[15]Stames HB,Patel AA,Stouffer GA.Optimal use of platelet glycoproteinⅡb/Ⅲa receptor antagonists in patients undergoing percutaneous coronary interventions[J].Drugs,2011,71(15):2009.
[16]Valgimigli M,Tebaldi M.Safety evaluation of tirofiban[J].Expert Opin Drug Saf,2010,9(5):801.
[17]Huynh T,Piazza N,DiBattiste PM,et al.Analysis of bleeding complications associated with glycoproteinⅡb/Ⅲa receptors blockade in patients with high-risk acute coronary syndromes:insights from the PRISM-PLUS study[J].Int J Cardiol,2005,100(1):73.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2016.01.005
中图分类号:R969
引用信息:
[1]李晓烨,吴鸿谊,张钧睿,等.替罗非班相关血小板减少的危险因素分析[J].中国临床药学杂志,2016,25(01):16-20.DOI:10.19577/j.cnki.issn10074406.2016.01.005.
2014-10-31
2014
2015-09-17
2015-12-24
2015
2
2016-01-25
2016-01-25